Answers are grounded in this paper and cite their sources.
TNBC tumor models, Olp-Cur@Trf NAs demonstrated extended blood circulation and active tumor accumulation, resulting in markedly superior tumor growth inhibition compared to the free drug combination. Importantly, these nanoassemblies were well-tolerated with minimal systemic toxicity, as evidenced by the absence of detectable damage to major organs. Collectively, our results validated the application of Olp-Cur@Trf NAs as a promising and practical therapeutic strategy to reverse BCRP-mediated chemoresistance in TNBC, with significant implications for clinical translation.
No takes yet. Share an insight, caveat, or question.
Razzaq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: